Raised HDL cholesterol in Fabry disease: Response to enzyme replacement therapy

被引：16

作者：

Cartwright, DJ ^{[1
]}

Cole, AL ^{[1
]}

Cousins, AJ ^{[1
]}

Lee, PJ ^{[1
]}

机构：

[1] UCL Natl Hosp Neurol & Neurosurg, Charles Dent Metab Unit, London WC1N 3BG, England

来源：

JOURNAL OF INHERITED METABOLIC DISEASE | 2004年 / 27卷 / 06期

关键词：

D O I：

10.1023/B:BOLI.0000045841.27968.06

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Fabry disease patients have increased risk of vascular disease despite cardioprotective increased HDL-cholesterol. Enzyme therapy does not significantly alter the lipid profile in the short term.

引用

页码：791 / 793

页数：3

共 3 条

[1] Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease. [J].

Eng, CM ;

Guffon, N ;

Wilcox, WR ;

Germain, DP ;

Lee, P ;

Waldek, S ;

Caplan, L ;

Linthorst, GE ;

Desnick, RJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (01) :9-16

[2]

ESNICK RJ, 2001, METABOLIC MOL BASES, P3733

[3] The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert group recommendations [J].

Sacks, FM .

AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (02) :139-+

← 1 →